Cargando…
BRCA1 expression and improved survival in ovarian cancer patients treated with intraperitoneal cisplatin and paclitaxel: a Gynecologic Oncology Group Study
BACKGROUND: Breast cancer 1, early onset (BRCA1) is a tumour-suppressor gene associated with familial epithelial ovarian cancer (EOC). Reduced BRCA1 expression is associated with enhanced sensitivity to platinum-based chemotherapy. We sought to examine the prognostic relevance of BRCA1 expression in...
Autores principales: | Lesnock, J L, Darcy, K M, Tian, C, DeLoia, J A, Thrall, M M, Zahn, C, Armstrong, D K, Birrer, M J, Krivak, T C |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3619264/ https://www.ncbi.nlm.nih.gov/pubmed/23462720 http://dx.doi.org/10.1038/bjc.2013.70 |
Ejemplares similares
-
Assessment of the Prognostic Value of Two Common Variants of BRCA1 and BRCA2 Genes in Ovarian Cancer Patients Treated with Cisplatin and Paclitaxel: A Gynecologic Oncology Group Study
por: Tian, Chunqiao Q., et al.
Publicado: (2013) -
Differential Analysis of Ovarian and Endometrial Cancers Identifies a Methylator Phenotype
por: Kolbe, Diana L., et al.
Publicado: (2012) -
Systemic exposure to cisplatin and paclitaxel after intraperitoneal chemotherapy in ovarian cancer
por: de Jong, Loek A. W., et al.
Publicado: (2023) -
NIPEC with Single-Dose Intraperitoneal Cisplatin and Paclitaxel in Stage III Epithelial Ovarian Cancer
por: Saldanha, Elroy, et al.
Publicado: (2022) -
A Dose-Finding Trial for Hyperthermic Intraperitoneal Cisplatin in Gynecological Cancer Patients Receiving Hyperthermic Intraperitoneal Chemotherapy
por: Chan, Chui-ying, et al.
Publicado: (2021)